| Market Cap | 5.93B | P/E | 32.18 | EPS this Y | - | Ern Qtrly Grth | 293.30% |
| Income | 190M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 11.00% |
| Sales | 2.88B | PEG | - | EPS past 5Y | - | 200D Avg Chg | 28.00% |
| Dividend | 1.00% | Price/Book | 2.77 | EPS next 5Y | - | 52W High Chg | -1.00% |
| Recommedations | - | Quick Ratio | 0.82 | Shares Outstanding | 110.94M | 52W Low Chg | 114.00% |
| Insider Own | - | ROA | 8.46% | Shares Float | 154.66M | Beta | 0.44 |
| Inst Own | - | ROE | 8.81% | Shares Shorted/Prior | -/- | Price | 53.75 |
| Gross Margin | 48.94% | Profit Margin | 6.61% | Avg. Volume | 358 | Target Price | - |
| Oper. Margin | 21.41% | Earnings Date | Feb 22 | Volume | 63 | Change | 0.00% |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.